ClinicalTrials.gg
RecruitingNCT07555938CEVOLUTIONUpdated Nov 10, 2026

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

A Phase 3 interventional study of Cevostamab and Pomalidomide in Multiple Myeloma, sponsored by Hoffmann-La Roche. Recruiting at 103 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 10, 2026First sites in France and United KingdomEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.

Planned enrollment
Largest of 29
380 · median 90
Started
2026
with 3 others
Phase 3
2 of 30
1 open now
Primary completion
2028-10
later than 4 of 11 live
Registered
28th of 30
by date

Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one has the largest planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 28th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Multiple Myeloma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.
  • Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
  • MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
  • Received one to three that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide
  • Participants must have during screening

Exclusion criteria

Exclusion Criteria:

  • Known history of systemic light chain amyloidosis with major organ involvement (e.g., positive Congo Red stain or equivalent in tissue or documented within serum amyloid P component scan)
  • Known history or current plasma cell leukemia
  • GI disease that might significantly alter absorption of oral drugs
  • Participants must not have any ongoing CNS disease or non-secretory myeloma
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Cevostamab + Pomalidomide + Dexamethasone

    Cevostamab will be administered intravenously on a 21-day cycle in cycle 1 and on a 28-day cycle from cycle 2 onwards. Pomalidomide will be administered orally (PO) on a 28-day cycle from cycle 2 onwards. Dexamethasone will be administered as a premedication prior to cevostamab.

    Drug: Cevostamab · Drug: Pomalidomide · Drug: Dexamethasone

  • Active comparator
    Standard of Care (SOC)

    Participants will receive investigator's choice of one SOC regimen.

    Drug: Pomalidomide · Drug: Dexamethasone · Drug: Daratumumab · Drug: Elotuzumab · Drug: Carfilzomib

Interventions

  • Participants will receive cevostamab IV as per the schedule given in the protocol.

  • Participants will receive pomalidomide tablet orally PO as per the schedule given in the protocol.

  • Participants will receive dexamethasone tablet orally PO or IV as per the schedule given in the protocol.

  • Participants will receive daratumumab SC as per the schedule given in the protocol.

  • Participants will receive elotuzumab IV as per the schedule given in the protocol.

  • Participants will receive carfilzomib IV as per the schedule given in the protocol.

06

What researchers measure

Primary outcomes

  1. Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate

    Time frame: Up to 1 year after the last participant is randomized

  2. Progression-Free Survival (PFS)

    Time frame: Up to 5 years after the last participant is randomized

Secondary outcomes

  1. Very Good Partial Response (VGPR) or Better Rate

    Time frame: Up to 5 years after the last participant is randomized

  2. Overall Survival (OS)

    Time frame: Up to 5 years after the last participant is randomized

  3. Change in Disease Symptoms as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20)

    Primary domains: fatigue, pain, physical functioning, cognitive functioning and global health status.

    Time frame: From baseline to Month 6

  4. Overall Response Rate (ORR)

    Time frame: Up to 5 years after the last participant is randomized

  5. Complete Response (CR) Rate

    Time frame: Up to 5 years after the last participant is randomized

  6. Time to Response (TTR)

    Time frame: Up to 5 years after the last participant is randomized

  7. Time to Best Response (TTBR)

    Time frame: Up to 5 years after the last participant is randomized

  8. Duration of Response (DOR)

    Time frame: Up to 5 years after the last participant is randomized

  9. Progression-Free Survival (PFS)

    Time frame: Up to 5 years after the last participant is randomized

  10. Progression-Free Survival 2 (PFS2)

    Time frame: Up to 5 years after the last participant is randomized

  11. Overall MRD-Negative Complete Response Rate

    Time frame: Up to 5 years after the last participant is randomized

  12. Overall MRD-Negative Rate

    Time frame: Up to 5 years after the last participant is randomized

  13. Sustained MRD-Negative CR Rate

    Time frame: At 6, 12, and 24 months

  14. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to 5 years after the last participant is randomized

  15. Tolerability as Assessed by the Incidence of Dose Interruptions, Dose Reductions, Dose Intensity, and Treatment Discontinuation

    Time frame: Up to 5 years after the last participant is randomized

  16. Number of Participants With Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Function of Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed NCI PRO-CTCAE

    Time frame: Up to 5 years after the last participant is randomized

  17. Change From Baseline in Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)

    Time frame: Baseline and up to 5 years after the last participant is randomized

  18. Change From Cycle 1 Day 8 in Treatment-Related Side Effect Bother as Assessed by the Functional Assessment of Cancer Therapy-General, General Population 5 (FACTG GP5)

    Time frame: At Day 8 of Cycle 1, up to 5 years after the last participant is randomized. Cycle 1 is 21 days.

  19. Change From Baseline in the Disease Symptom Scale of the EORTC QLQ-MY20

    Time frame: Baseline and Up to 5 years after the last participant is randomized

  20. Change from Baseline in the Global Health Status/Quality of Life (GHS/QoL) of the EORTC QLQ-Core 30 (C30)

    Time frame: Baseline and Up to 5 years after the last participant is randomized

  21. Time to Confirmed Deterioration in Disease Symptoms, as Assessed by EORTC QLQ-MY20

    Time frame: Up to 5 years after the last participant is randomized

  22. Time to Confirmed Deterioration in GHS/QoL as Assessed by the EORTC QLQ-C30

    Time frame: Up to 5 years after the last participant is randomized

  23. Change From Baseline in Fatigue as Assessed by the EORTC QLQ-C30

    Time frame: Baseline and up to 5 years after the last participant is randomized

  24. Time to Confirmed Deterioration in Fatigue as Assessed by the EORTC QLQ-C30

    Time frame: Up to 5 years after the last participant is randomized

  25. Percentage of Participants Experiencing Clinically Meaningful Improvement in Disease Symptoms as Assessed by the EORTC QLQ-MY20

    Time frame: Up to 5 years after the last participant is randomized

  26. Percentage of Participants Experiencing Clinically Meaningful Improvement in GHS/QoL as Assessed by the EORTC QLQ-C30

    Time frame: Up to 5 years after the last participant is randomized

  27. Percentage of Participants Experiencing Clinically Meaningful Improvement in Fatigue as Assessed by the EORTC QLQ-C30

    Time frame: Up to 5 years after the last participant is randomized

  28. Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline and with ADAs to Cevostamab During the Study

    Time frame: Baseline and up to 5 years after the last participant is randomized

07

Study locations

103 of 103 sites recruiting

Showing the first 100 of 103 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2028, 28 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 28 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Jan 31, 2033
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
28 sites added — first sites in France and United Kingdom
Show 28 added (7 France, 4 United States, 4 United Kingdom, 3 Italy, 2 Denmark, 2 Poland, 2 Spain, 1 Australia, 1 China, 1 Brazil, 1 Czechia)
  • MD Anderson Cancer Center · Houston, United States
  • The Alfred Hospital · Melbourne, Australia
  • Tianjin Institute of Hematology & Blood Diseases Hospital · Tianjin, China
  • Rigshospitalet · København Ø, Denmark
  • CHU de Nantes - Hôtel-Dieu · Nantes, France
  • CHRU de Lille - Hopital Claude Huriez · Lille, France
  • CHU Lyon - Centre Hospitalier Lyon Sud · Pierre-Benite (Lyon), France
  • CHU de Poitiers - La Miletrie · Poitiers, France
  • CHU de Toulouse -Service d'Hématologie · Toulouse, France
  • Policlinico S.Orsola-Malpighi · Bologna, Italy
  • AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette · Turin, Italy
  • Uniwersytecki Szpital Kliniczny w Poznaniu · Późna, Poland
  • SP Szpital Kliniczny nr 1 Pomorskiej Akademii Medycznej im. prof. Tadeusza Sokolowskiego · Szczecin, Poland
  • Institut Catala d?Oncologia Hospital Germans Trias i Pujol · Badalona, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • University College London Hospitals NHS Foundation Trust · London, United Kingdom
  • Oxford Churchill Hospital · Oxford, United Kingdom
  • The Royal Wolverhampton Hospitals NHS Trust · Wolverhampton, United Kingdom
  • University of Illinois · Chicago, United States
  • Perelman Center for Advanced Medicine · Philadelphia, United States
  • Medical College of Wisconsin · Milwaukee, United States
  • Americas Centro de Oncologia Integrado · Rio de Janeiro, Brazil
  • Fakultni nemocnice Brno · Brno, Czechia
  • Sjællands Universitetshospital, Køge;Hæmatologisk afdeling · Køge, Denmark
  • Hopital de L'Archet · Nice, France
  • Hopitaux De Brabois · Vandœuvre-lès-Nancy, France
  • Policlinico Umberto I · Rome, Italy
  • Barts Health NHS Trust · London, United Kingdom
across 2 updates, Oct 13, 2026 – Nov 10, 2026
Eligibility
1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Exclusion criteria
  • EditedKnown history of systemic light chain amyloidosis with major organ involvement (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
  • RemovedPlasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells
  • AddedKnown history or current plasma cell leukemia
Nov 10, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedTime to Confirmed DeteriorationChange in the Disease Symptoms Scale as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20)Time frame: Up to 5 years after the last participant is randomized → From baseline to Month 6
  • AddedTime to Confirmed Deterioration in Disease Symptoms, as Assessed by EORTC QLQ-MY20Time frame: Up to 5 years after the last participant is randomized
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    10 sites added
    Show 10 added (3 United States, 2 France, 1 Brazil, 1 Czechia, 1 Denmark, 1 Italy, 1 United Kingdom)
    • University of Illinois · Chicago, United States
    • Perelman Center for Advanced Medicine · Philadelphia, United States
    • Medical College of Wisconsin · Milwaukee, United States
    • Americas Centro de Oncologia Integrado · Rio de Janeiro, Brazil
    • Fakultni nemocnice Brno · Brno, Czechia
    • Sjællands Universitetshospital, Køge;Hæmatologisk afdeling · Køge, Denmark
    • Hopital de L'Archet · Nice, France
    • Hopitaux De Brabois · Vandœuvre-lès-Nancy, France
    • Policlinico Umberto I · Rome, Italy
    • Barts Health NHS Trust · London, United Kingdom
    Eligibility 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • EditedKnown history of systemic light chain amyloidosis with major organ involvement (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
    • RemovedPlasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells
    • AddedKnown history or current plasma cell leukemia
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedTime to Confirmed DeteriorationChange in the Disease Symptoms Scale as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20)Time frame: Up to 5 years after the last participant is randomized → From baseline to Month 6
    • AddedTime to Confirmed Deterioration in Disease Symptoms, as Assessed by EORTC QLQ-MY20Time frame: Up to 5 years after the last participant is randomized
    + 1 other change: verification date
  2. Oct 13, 2026
    18 sites added — first sites in France and United Kingdom
    Show 18 added (5 France, 3 United Kingdom, 2 Italy, 2 Poland, 2 Spain, 1 United States, 1 Australia, 1 China, 1 Denmark)
    • MD Anderson Cancer Center · Houston, United States
    • The Alfred Hospital · Melbourne, Australia
    • Tianjin Institute of Hematology & Blood Diseases Hospital · Tianjin, China
    • Rigshospitalet · København Ø, Denmark
    • CHU de Nantes - Hôtel-Dieu · Nantes, France
    • CHRU de Lille - Hopital Claude Huriez · Lille, France
    • CHU Lyon - Centre Hospitalier Lyon Sud · Pierre-Benite (Lyon), France
    • CHU de Poitiers - La Miletrie · Poitiers, France
    • CHU de Toulouse -Service d'Hématologie · Toulouse, France
    • Policlinico S.Orsola-Malpighi · Bologna, Italy
    • AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette · Turin, Italy
    • Uniwersytecki Szpital Kliniczny w Poznaniu · Późna, Poland
    • SP Szpital Kliniczny nr 1 Pomorskiej Akademii Medycznej im. prof. Tadeusza Sokolowskiego · Szczecin, Poland
    • Institut Catala d?Oncologia Hospital Germans Trias i Pujol · Badalona, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • University College London Hospitals NHS Foundation Trust · London, United Kingdom
    • Oxford Churchill Hospital · Oxford, United Kingdom
    • The Royal Wolverhampton Hospitals NHS Trust · Wolverhampton, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07555938
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jun 23, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Jan 31, 2033 (estimated)
Last update
Nov 10, 2026

Study contacts

Reference Study ID Number: CO46096 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cevostamab

Start the discussion